Jade Biosciences Inc., a biotechnology company specializing in therapies for autoimmune diseases, announced plans to initiate a clinical study of its anti-APRIL monoclonal antibody, JADE101, in healthy volunteers in the latter half of 2025. This study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and biomarker suppression of JADE101, specifically targeting APRIL and IgA. Interim results from this study are expected in the first half of 2026, which will aid in determining appropriate dosing for future studies in patients with IgA nephropathy (IgAN). Preclinical data, presented at the 62nd European Renal Association Congress, highlighted JADE101's potential for best-in-class efficacy with convenient dosing intervals. A conference call and webcast regarding these developments were held on June 9, 2025.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。